A PYMNTS Company

Has the Administrative Court’s Reversal of the IAA Decision in Pfizer Got It Right?

BY | October 16, 2012

Daniela Ampollini, Oct 15, 2012 In my article, Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case, which appeared in the July (2) issue of…

Daniela Ampollini, Oct 15, 2012

In my article, Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case, which appeared in the July (2) issue of the CPI Antitrust Chronicle, I discussed the reasons the Italian Antitrust Authority (“IAA”) found Pfizer liable of abuse of dominant position from a patent law perspective. I attempted to reconcile-without succeeding, in fact-the reasoning of the IAA with the meaning and function of the various patent law cat

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.211.117.197

Please verify email or join us to access premium content!